Table 2.

Clinical efficacy in patients grouped by baseline CRP levels: <10 mg/L and ≥10 mg/L

	Week	Baseline CRP levels <10 mg/L		Baseline CRP levels ≥10 mg/L
		Pooled secukinumab 150 mg (N=110)	Pooled placebo (N=102)	Pooled secukinumab 150 mg (N=87)	Pooled placebo (N=93)
ASAS20, %	16	51.8**	29.4	72.4****	28.0
	156	63.0	–	83.3	–
ASAS40, %	16	33.6***	9.8	47.1****	15.1
	156	44.5	–	70.3	–
BASDAI, mean change from baseline	16	−1.99****	−0.86	−2.78****	−0.62
	156	−2.73	–	−3.62	–
BASDAI50, %	16	30.0**	10.8	41.4****	7.5
	156	46.0	–	61.8	–
ASDAS inactive disease, %	16	20.0**	4.9	12.6*	1.1
	156	28.9	–	15.6	–
ASAS partial remission, %	16	16.4**	2.9	12.6*	4.3
	156	21.7	–	31.1	–

*p<0.05; **p<0.01; ***p<0.001; ****p<0.0001 vs placebo; missing values were imputed as non-response at week 16. MI and MMRM data presented at week 156 included n=88 and 71 in baseline CRP levels <10 mg/L and ≥10 mg/L, respectively. For BASDAI, LS mean change from baseline was presented using MMRM at weeks 16 and 156.

ASAS, Assessment of SpondyloArthritis international Society criteria; ASDAS, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; CRP, C-reactive protein; LS, least squares; MI, multiple imputation; MMRM, mixed-effect model repeated measures; N, number of patients included in this pooled study at week 16; n, number of patients in this pooled study at week 156.